Biotech Values

[dewophile]

yup - definitely room for improved agents in this class
treatment in pregnancy (where i have some first hand experience) is increasingly common and particularly challenging:
1. pregnancy is a prothrombotic condition
2. there is an increasing appreciation that clotting in the placenta may be a predisposing factor to many complications of pregnancy, including miscarriage
3. there are more and more genetic screens for heritable thrombophilias, increasing the total size of the market for prophylaxis in pregnancy
4. coumadin is teratogenic and not an option
5. peripartum bleeding is always a concern, and managing anticoagulation at term is vexing to say the least
6. the half-life of unfractionated heparin usually requires multiple daily dosing (not to mention onerous monitoring), and hence LMW heparins have largely replaced heparin..although limited reversibility is a drawback as you point out

if mnta (or anyone else) can improve the treatment options its a blockbuster in the making imo